EXHALED NITRIC OXIDE AND AEROALLERGEN SENSITIZATION IN ASTHMATIC CHILDREN
DOI:
https://doi.org/10.46793/PP151107009ZKeywords:
asthma, children, nitric oxide, senzitisationAbstract
Introduction: The examination of nitric oxide in exhaled air concentration in children suffering from asthma and to establish the relation with the degree of sensitization to aeroallergens.
Material and Methods: The examination included fifty-two children (aged 12.40 ± 2.35 years), twenty-eight male (53.85%) and twenty-four female (46.15%), with the average length of suffering from asthma 8.33 ± 3.93 years. The degree of sensitization to aeroallergens was determined by skin prick testing and assessed using the atopic index (AI).
Results: The average value of FeNO in exhaled air of children suffering from stable allergic asthma was 43.92 ± 35.63 ppb, and after a four week anti-inflammatory treatment it decreased to 34.92 ± 32.04 ppb (p<0.05). In relation to AI, the level of FeNO in exaled air was 41.00 vs. 40.69 vs 50.88 ppb, in the given order without statistically significant difference. The highest values of FeNO in exhaled air were present in children suffering from a mixed type of sensitisation, 56.85 ppb (Me 48.50) in comparison to sensitisation to seasonal allergens 15.29 ppb (Me 12) and indoor allergens 32.22 ppb (Me 26). Allergic rhinitis, the duration of asthma and the gender were not significantly related to the values of FeNO in exhaled breath, while significant was the negative correlation between the body mass index and FeNO, r = -0,43 (p˂0.01).
Conclusion: Children suffering from allergic asthma possess increased values of nitric oxide in exhaled air, which is a useful indicator of daily dosage adjustment in patients treated with anti-inflammatory drugs
References
Global Strategy for Asthma Management and Prevention. Definition, description and diagnosis of asthma. GINA 2015; 2-11.
Shaw DE, Wilson E, Pavord ID. Exhaled nitric oxide in asthma.Eur Respir Mon 2010; 49: 32–44.
Silvestri M, Sabatini F, Spallarossa D et al. Exhaled nitric oxide levels in non-allergic and allergic mono- or polysensitised children with asthma. Thorax 2001; 56:857-862.
Korsch L, Hombach A, Schnegg C and al. Differences in Exhaled Nitric Oxide in Non-and Mono- or Polysensitised Allergic Children with Asthma bronchiale. The Open Pediatr Med J 2008; 2: 30-34.
Scott M, Raza A, Karmaus W at al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax 2010; 65:258-262. DOI:10.1136/thx.2009.125443
Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax 1999; 54:268-72.
Wilson AM, Duong M, Pratt B, et al. Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients. Allergy 2006; 61: 537–542.
Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005; 172: 453–459.
Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233–242.
Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117: 45–52.
Montuschi P, Mondino C, Koch P, et al. Effects of montelukast treatment and withdrawal on fractional exhaled nitric oxide and lung function in children with asthma. Chest 2007; 132: 1876–1881.
Fritscher LG, Rodrigues MT, Zamel N, et al. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir Med 2009; 103: 296–300.
Straub DA, Minocchieri S, Moeller A, et al. The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest 2005; 127: 509–514.
Shaw DE, Wilson E, Pavord ID. Exhaled nitric oxide in asthma. Eur Respir Mon 2010; 49: 32-44.
Dweik RA, Boggs P, Erzurum SC et al. An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. Am J Respir Crit Care Med 2011;l 184: 602–615. DOI: 10.1164/rccm.912011ST
LaForce C, Brooks E ; Herje N et al. Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic. Ann Allergy Asthma Immunol 2014; 113: 619-623.
